On Jan 13, Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) announced that the first cohort of patients in the BP-004 trial has completed dosing with the Company’s genetically engineered donor T cells (BPX-501), after receiving a partial T depleted haplo-identical allogeneic hematopoietic stem cell transplant (haplo-HSCT). On Thursday shares of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) closed at $26.87.
On Jan. 12, Celgene Corporation (NASDAQ:CELG) provided preliminary 2014 results and financial outlook for 2015. In 2015, total net product sales are expected to be approximately $9,000 million to $9,500 million, a 22 percent increase year-over-year, based on the mid-point of the range. Celgene Corporation (NASDAQ:CELG) in last trading activity decreased -2.34% to close at $118.27. Company weekly performance is 2.80% while its quarterly performance stands at 36.65%. Celgene Corporation (NASDAQ:CELG) is -4.47% away from its 52 week high.
Uranium Energy Corp. (NYSE:UEC) saw a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 11,430,633 shares, a growth of 3.5% from the December 15th total of 11,040,565 shares, American Banking & Market News reports. On last trading day Uranium Energy Corp. (NYSEMKT:UEC) decreased -9.16% to close at $1.19. Its volatility for the week is 8.31% while volatility for the month is 6.93%. UEC’s EPS growth for past 5 years was -1.40%. Uranium Energy Corp. (NYSEMKT:UEC) monthly performance is -32.39%.
NN Inc. (NASDAQ:NNBR) announced four newly created positions to the Group: Rob Heinrich named Vice President/General Manager of the Global Rollers Division; Dario Galetti named Vice President/General Manager of the Global Ball Division; Jeff Hodge named Vice President of Business Development and Trevor Lynch named Group Controller. NN Inc. (NASDAQ:NNBR) has 0.70% insider ownership while its institutional ownership stands at 78.40%. In last trading activity company’s stock closed at $21.10.
Benchmark Co. reiterated their buy rating on shares of Perion Network (NASDAQ:PERI) in a research report sent to investors on Thursday morning. The firm currently has a $8.00 price target on the stock, down from their previous price target of $10.00. On last trading day Perion Network Ltd. (NASDAQ:PERI) advanced 3.09% to close at $3.34. Its volatility for the week is 6.25% while volatility for the month is 4.85%. PERI’s sales growth for past 5 years was 31.80% and its EPS growth for past 5 years was -46.60%. Perion Network Ltd. (NASDAQ:PERI) monthly performance is -27.23%.